CG Oncology
CGON
142 hedge funds and large institutions have $1.74B invested in CG Oncology in 2025 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 62 increasing their positions, 34 reducing their positions, and 24 closing their positions.
82% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 34
34% more call options, than puts
Call options by funds: $1.15M | Put options by funds: $859K
4.46% more ownership
Funds ownership: 88.38% → 92.84% (+4.5%)
1% more funds holding
Funds holding: 140 → 142 (+2)
8% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 24
8% less capital invested
Capital invested by funds: $1.9B → $1.74B (-$160M)
17% less funds holding in top 10
Funds holding in top 10: 12 → 10 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$38.2M |
| 2 |
O
OrbiMed
New York
|
+$29.3M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$27M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$19.4M |
| 5 |
Millennium Management
New York
|
+$9.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$20.1M |
| 2 |
PA
Perceptive Advisors
New York
|
-$12M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$5.85M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$5.74M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$5.68M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
151
Jane Street
New York
| – | -$1.76M | -61,362 | Closed |
|
152
Alyeska Investment Group
Chicago,
Illinois
| – | -$1.29M | -45,000 | Closed |
|
|
MIM
153
Monashee Investment Management
Boston,
Massachusetts
| – | -$1.06M | -36,872 | Closed |
|
|
XT
154
XTX Topco
George Town,
Cayman Islands
| – | -$573K | -19,996 | Closed |
|
155
M&T Bank
Buffalo,
New York
| – | -$485K | -16,891 | Closed |
|
|
UOC
156
UBS O'Connor
Chicago,
Illinois
| – | -$368K | -12,834 | Closed |
|
157
Squarepoint
New York
| – | -$313K | -10,907 | Closed |
|
|
ZP
158
Zimmer Partners
New York
| – | -$287K | -10,000 | Closed |
|
|
MAM
159
Meeder Asset Management
Dublin,
Ohio
| – | -$189K | -6,578 | Closed |
|
|
VEA
160
Virtus ETF Advisers
New York
| – | -$70.6K | -2,463 | Closed |
|
|
MCI
161
MRP Capital Investments
Alpharetta,
Georgia
| – | -$1.15K | -40 | Closed |
|
162
Osaic Holdings
Scottsdale,
Arizona
| – | -$1K | -35 | Closed |
|
|
QT
163
Quantbot Technologies
New York
| – | -$201 | -7 | Closed |
|
|
PA
164
Parallel Advisors
San Francisco,
California
| – | -$86 | -3 | Closed |
|
|
IA
165
IFP Advisors
Tampa,
Florida
| – | -$29 | -1 | Closed |
|
CGON Hedge Fund Activity: Q1 2025 in Review
142 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in CG Oncology (CGON) for Q1 2025, worth a combined $1.74B — down 8.4% from $1.9B a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new CGON positions and 24 closed out — a net gain of 2 holders — while 62 added to existing stakes and 34 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $38.2M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $20.1M sold.
- 142 institutional investors held CG Oncology (CGON) as of Q1 2025, up from 140 in Q4 2024.
- Funds reported $1.74B of CG Oncology stock for Q1 2025, down 8.4% quarter-over-quarter.
- 26 funds opened new CG Oncology positions in Q1 2025 and 24 closed out, a net change of +2 holders.
- The largest CG Oncology buyer in Q1 2025 was Point72 Asset Management, an estimated $38.2M added.
- The largest CG Oncology seller in Q1 2025 was Avoro Capital Advisors, an estimated $20.1M sold.
Based on aggregated 13F filings for Q1 2025.